secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001213900-24-041919
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen amends securities purchase agreement with Alpha to add 4.99% beneficial ownership cap
--------------------------------------------------------------------------------

- Amendment dated May 13, 2024 to the May 7, 2024 Securities Purchase Agreement with Generating Alpha Ltd.
- New Section 4(x) prohibits issuance of common stock that would cause Alpha and affiliates to beneficially own more than 4.99% of outstanding shares.
- Beneficial ownership determined per Section 13(d) of the Exchange Act and Regulation 13D-G.
- All other terms of the original Purchase Agreement remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390024041919/0001213900-24-041919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390024041919/ea0205884-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-041919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer